Development of coronary heart disease and ischemic stroke in relation to fasting and 2-hour plasma glucose levels in the normal range.
BACKGROUND
Individuals who had normoglycemia but whose 2-hour plasma glucose (2hPG) concentrations did not return to the fasting plasma glucose (FPG) levels during an oral glucose tolerance test (OGTT) have been shown to have increased cardiovascular mortality. This is further investigated regarding to the first events of coronary heart disease (CHD) and ischemic stroke (IS).


METHODS
Data from 9 Finnish and Swedish cohorts comprising 3743 men and 3916 women aged 25 to 90  years who had FPG < 6.1 mmol/l and 2hPG < 7.8 mmol/l and free of CVD at enrollment were analyzed. Hazard ratios (HRs) for first CHD and IS events were estimated for the individuals with 2hPG > FPG (Group II) compared with those having 2hPG ≤ FPG (Group I).


RESULTS
A total of 466 (115) CHD and 235 (106) IS events occurred in men (women) during a median follow-up of 16.4 years. Individuals in Group II were older and had greater body mass index, blood pressure, 2hPG and fasting insulin than those in Group I in both sexes. Multivariate adjusted HRs (95% confidence intervals) for incidence of CHD, IS, and composite CVD events (CHD + IS) in men were 1.13 (0.93-1.37), 1.40 (1.06-1.85) and 1.20 (1.01-1.42) in the Group II as compared with those in the Group I. The corresponding HRs in women were 1.33 (0.83-2.13), 0.94 (0.59-1.51) and 1.11 (0.79-1.54), respectively.


CONCLUSIONS
Within normoglycemic range individuals whose 2hPG did not return to their FPG levels during an OGTT had increased risk of CHD and IS.
Department of Public Health, Hjelt Institute, University of Helsinki, Helsinki, Finland. feng.ning@helsinki.fi
Feng
F
Ning
Lei
L
Zhang
Jacqueline M
JM
Dekker
Altan
A
Onat
Coen D A
CD
Stehouwer
John S
JS
Yudkin
Tiina
T
Laatikainen
Jaakko
J
Tuomilehto
Kalevi
K
Pyörälä
Qing
Q
Qiao
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism*; D002545:Brain Ischemia / Q000097:blood* / Q000453:epidemiology* / Q000401:mortality; D016009:Chi-Square Distribution; D003327:Coronary Disease / Q000097:blood* / Q000453:epidemiology* / Q000401:mortality; D005215:Fasting / Q000097:blood*; D005260:Female; D005387:Finland / Q000453:epidemiology; D005951:Glucose Tolerance Test; D006801:Humans; D015994:Incidence; D007328:Insulin / Q000097:blood; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012016:Reference Values; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000097:blood* / Q000453:epidemiology* / Q000401:mortality; D016019:Survival Analysis; D013548:Sweden / Q000453:epidemiology; D013997:Time Factors
D015415:Biomarkers; D001786:Blood Glucose; D007328:Insulin